Peter A Vandenberghe

List of Publications by Year
in descending order

280	19,695	14614 66	11581 135
papers	citations	h-index	g-index

288	288	288	20222
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Overactive WASp in X-linked neutropenia leads to aberrant B-cell division and accelerated plasma cell generation. Journal of Allergy and Clinical Immunology, 2022, 149, 1069-1084.	1.5	5
2	COVID-19 Vaccination Safety and Tolerability in Patients Allegedly at High Risk for Immediate Hypersensitivity Reactions. Vaccines, 2022, 10, 286.	2.1	8
3	Combined lenalidomide/bortezomib for multiple myeloma complicated by fulminant myocarditis: a rare case report of widely used chemotherapy. European Heart Journal - Case Reports, 2022, 6, ytac093.	0.3	4
4	Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients. OncoTargets and Therapy, 2022, Volume 15, 243-250.	1.0	4
5	Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets. Clinical Chemistry, 2022, 68, 1164-1176.	1.5	6
6	Ultra-low coverage whole genome sequencing of ccfDNA in multiple myeloma: A tool for laboratory routine?. Cancer Treatment and Research Communications, 2021, 28, 100380.	0.7	3
7	Constitutive activation of WASp leads to abnormal cytotoxic cells with increased granzyme B and degranulation response to target cells. JCI Insight, 2021, 6, .	2.3	7
8	BIRD-2, a BH4-domain-targeting peptide of Bcl-2, provokes Bax/Bak-independent cell death in B-cell cancers through mitochondrial Ca2+-dependent mPTP opening. Cell Calcium, 2021, 94, 102333.	1.1	28
9	14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T and myeloid immature acute leukemia. Blood, 2021, 138, 773-784.	0.6	19
10	Case Report: Spontaneous Remission of an Infraorbital Follicular B-Cell Lymphoma: Case Report and Review of the Literature. Pathology and Oncology Research, 2021, 27, 642433.	0.9	0
11	The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA. Blood Advances, 2021, 5, 1991-2002.	2.5	15
12	Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies. EClinicalMedicine, 2021, 35, 100856.	3.2	42
13	An Update of Safety and Efficacy Results from Phase 1 Dose-Escalation and Expansion Study of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing Prior TKI Therapies. Blood, 2021, 138, 309-309.	0.6	3
14	Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. Blood, 2020, 135, 1685-1695.	0.6	28
15	Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. Pharmaceutics, 2020, 12, 194.	2.0	40
16	The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. Nature Communications, 2020, 11, 1044.	5.8	81
17	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. OncoImmunology, 2020, 9, 1703449.	2.1	156
18	Ultraâ€low depth sequencing of plasma cell <scp>DNA</scp> for the detection of copy number aberrations in multiple myeloma. Genes Chromosomes and Cancer, 2020, 59, 465-471.	1.5	3

#	Article	IF	Citations
19	In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy. Cancer Immunology, Immunotherapy, 2020, 69, 1751-1766.	2.0	36
20	FER and FES tyrosine kinase fusions in follicular T-cell lymphoma. Blood, 2020, 135, 584-588.	0.6	16
21	Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib. Blood, 2020, 136, 51-52.	0.6	20
22	Constitutive IP3 signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP3 receptor disruptor BIRD-2. Cell Death and Differentiation, 2019, 26, 531-547.	5.0	69
23	Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. Haematologica, 2019, 104, e17-e20.	1.7	18
24	Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes. Genes Chromosomes and Cancer, 2019, 58, 689-697.	1.5	8
25	Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis. Annals of Hematology, 2019, 98, 1421-1426.	0.8	14
26	Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Phâ€‰+â€‰ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia, 2019, 33, 1910-1922.	3.3	54
27	FIP1L1â€PDGFRÎ± p.T674Iâ€D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1â€PDGFRÎ± Positive Leukemia. HemaSphere, 2019, 3, e182.	1.2	1
28	Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors. Annals of Oncology, 2019, 30, 85-95.	0.6	35
29	A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. Haematologica, 2018, 103, 840-848.	1.7	45
30	Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project. Annals of Oncology, 2018, 29, 200-208.	0.6	25
31	Clinicopathological characteristics of de novo and secondary myeloid sarcoma: A monocentric retrospective study. European Journal of Haematology, 2018, 100, 603-612.	1.1	32
32	Other immunomodulatory agent-related lymphoproliferative diseases: a single-center series of 72 biopsy-confirmed cases. Modern Pathology, 2018, 31, 1457-1469.	2.9	6
33	EML1â€“ABL1 Is Activated by Coiledâ€Coilâ€Mediated Oligomerization and Induces Tâ€Cell Acute Lymphoblastic Leukemia or Myeloproliferative Disease in a Mouse Bone Marrow Transplant Model. HemaSphere, 2018, 2, e32.	1.2	2
34	Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients. Hematology, 2018, 23, 785-792.	0.7	23
35	Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia. Leukemia, 2018, 32, 1358-1369.	3.3	66
36	Improved survival after LTx-associated acute GVHD with mAb therapy targeting IL2RAb and soluble TNFAb: Single-center experience and systematic review. American Journal of Transplantation, 2018, 18, 3007-3020.	2.6	2

#	Article	IF	Citations
37	BCRâ€ABL1 positive Bâ€ALL can undergo Tâ€cell lineage shift to become CD19Ânegative Tâ€ALL. HemaSphere, 2018, 2, e42.	1.2	2
38	Constitutive activation of WASp in X-linked neutropenia renders neutrophils hyperactive. Journal of Clinical Investigation, 2018, 128, 4115-4131.	3.9	35
39	Unraveling the Landscape of Copy Number Aberrations in Hodgkin Lymphoma: A Joint KU Leuven and Lysa Study on Circulating Cell Free DNA. Blood, 2018, 132, 2836-2836.	0.6	0
40	Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. Blood, 2018, 132, 2861-2861.	0.6	0
41	Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. Blood, 2018, 132, 2838-2838.	0.6	1
42	Highly sensitive assays are mandatory for the differential diagnosis of patients presenting with symptoms of mast cell activation: diagnostic work-up of 38 patients. Acta Clinica Belgica, 2017, 72, 123-129.	0.5	2
43	Multipotent adult progenitor cells improve the hematopoietic function in myelodysplasia. Cytotherapy, 2017, 19, 744-755.	0.3	3
44	RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response. Leukemia, 2017, 31, 1706-1714.	3.3	49
45	An incidental finding of maternal multiple myeloma by non invasive prenatal testing. Prenatal Diagnosis, 2017, 37, 1257-1260.	1.1	13
46	Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene. Haematologica, 2017, 102, 1605-1616.	1.7	29
47	Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitorâ€“Sensitive and -Resistant Chronic Myeloid Leukemia. Clinical Cancer Research, 2017, 23, 2289-2300.	3.2	38
48	Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies. Genes Chromosomes and Cancer, 2016, 55, 428-441.	1.5	41
49	EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features. American Journal of Transplantation, 2016, 16, 414-425.	2.6	70
50	Secondary B-cell lymphoma associated with the Epstein-Barr virus in chronic lymphocytic leukemia patients. Journal of Hematopathology, 2016, 9, 113-120.	0.2	10
51	The role of the RAS pathway in iAMP21-ALL. Leukemia, 2016, 30, 1824-1831.	3.3	38
52	Circulating cell-free DNA in hematological malignancies. Haematologica, 2016, 101, 997-999.	1.7	16
53	A Lysa Phase II Study of Oral JAK1/2 Inhibitor Ruxolitinib in Advanced Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL). Blood, 2016, 128, 4160-4160.	0.6	2
54	IGH-Mediated Translocations, Recurrent in Classic Hodgkin Lymphoma, Frequently Correlate with an Aggressive Behavior. Blood, 2016, 128, 2922-2922.	0.6	1

#	Article	IF	Citations
55	Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern. Haematologica, 2015, 100, e275-e279.	1.7	76
56	The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. Blood, 2015, 125, 13-21.	0.6	168
57	Hedgehog pathway mutations in T-cell acute lymphoblastic leukemia. Haematologica, 2015, 100, e102-e105.	1.7	35
58	Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Haematologica, 2015, 100, 893-897.	1.7	49
59	t(15;21) translocations leading to the concurrent downregulation of RUNX1 and its transcription factor partner genes SIN3A and TCF12 in myeloid disorders. Molecular Cancer, 2015, 14, 211.	7.9	12
60	Validation of a locked nucleic acid based wild-type blocking PCR for the detection of EGFR exon 18/19 mutations. Diagnostic Pathology, 2015, 10, 57.	0.9	6
61	Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing. JAMA Oncology, 2015, 1, 814.	3.4	180
62	NUP98/11p15 translocations affect CD34+ cells in myeloid and T lymphoid leukemias. Leukemia Research, 2015, 39, 769-772.	0.4	12
63	Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. Lancet Haematology,the, 2015, 2, e55-e65.	2.2	115
64	Clonal chromosomal abnormalities in Ph-negative cells in chronic myeloid leukemia: an unusual case evolving to secondary acute myeloid leukemia. Cancer Genetics, 2015, 208, 102-104.	0.2	1
65	TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis. Molecular and Cellular Biology, 2015, 35, 2103-2118.	1.1	14
66	Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. Annals of Hematology, 2015, 94, 1927-1928.	0.8	51
67	Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia. Haematologica, 2015, 100, 1301-1310.	1.7	151
68	Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. Leukemia, 2015, 29, 1092-1103.	3.3	161
69	RPL5 Is a Candidate Tumor Suppressor on 1p22.1 in Multiple Myeloma of Which the Expression Is Linked to Bortezomib Response. Blood, 2015, 126, 2969-2969.	0.6	0
70	Identification of Candidate Oncogenes and Chromosomal Breakpoint Sequencing By Targeted Locus Amplification in T-Cell Acute Lymphoblastic Leukemia. Blood, 2015, 126, 1409-1409.	0.6	0
71	ALK-Positive Anaplastic Large Cell Lymphoma with the Variant EEF1G-, RNF213- and Atic-ALK Fusions Is Featured By Copy Number Gain of the Rearranged ALK Gene. Blood, 2015, 126, 3654-3654.	0.6	0
72	MPL p.S204P Is a Recurrent Mutation in Essential Thrombocythemia. Blood, 2015, 126, 2837-2837.	0.6	1

#	Article	IF	Citations
73	BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia. Blood, 2015, 126, 1569-1569.	0.6	0
74	Non-IG Aberrations of FOXP1 in B-Cell Malignancies Lead to an Aberrant Expression of N-Truncated Isoforms of FOXP1. PLoS ONE, 2014, 9, e85851.	1.1	18
75	Integrative Genomic and Transcriptomic Analysis Identified Candidate Genes Implicated in the Pathogenesis of Hepatosplenic T-Cell Lymphoma. PLoS ONE, 2014, 9, e102977.	1.1	48
76	Translocation t(1;11)(q21;q23): a new finding in congenital acute myeloid leukemia. Leukemia and Lymphoma, 2014, 55, 1435-1436.	0.6	2
77	Identification of a novel, recurrent MBTD1â€CXorf67 fusion in lowâ€grade endometrial stromal sarcoma. International Journal of Cancer, 2014, 134, 1112-1122.	2.3	117
78	Screening of <scp>JAK</scp>2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in <scp>SESN</scp>2, <scp>DNAJC</scp>17, <scp>ST</scp>13, <scp>TOP</scp>1<scp>MT</scp>, and <scp>NTRK</scp>1. British Journal of Haematology, 2014, 165, 734-737.	1.2	5
79	Suitability of Small Bronchoscopic Tumour Specimens for Lung Cancer Genotyping. Respiration, 2014, 88, 371-377.	1.2	10
80	A case with a cytogenetically cryptic variant of the inv(16)(p13q22)/t(16;16)(p13;q22). Cancer Genetics, 2014, 207, 231-232.	0.2	4
81	Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature, 2014, 508, 98-102.	13.7	261
82	An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia, 2014, 28, 1015-1021.	3.3	175
83	Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib. Annals of Hematology, 2014, 93, 2087-2089.	0.8	26
84	Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA. Experimental Hematology, 2014, 42, 282-293.e4.	0.2	41
85	Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. Blood, 2014, 123, 2229-2237.	0.6	135
86	In Vitro Characterization of Peripheral Blood Progenitor Cell Differentiation and Platelet Function in Essential Thrombocythemia (ET). Blood, 2014, 124, 1877-1877.	0.6	0
87	Analysis of Genotype, Phenotype and Outcome in a Belgian Cohort of Essential Thrombocythemia. Blood, 2014, 124, 5584-5584.	0.6	0
88	TAF10 Interacts with GATA1 Transcription Factor and Controls Mouse Erythropoiesis. Blood, 2014, 124, 2912-2912.	0.6	0
89	BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant. Blood, 2014, 124, 4512-4512.	0.6	1
90	Chromosomal translocations involving the IGH@ locus in B-cell precursor acute lymphoblastic leukemia: 29 new cases and a review of the literature. Cancer Genetics, 2013, 206, 162-173.	0.2	29

#	Article	IF	Citations
91	Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 186-190.	9.4	365
92	Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. Journal of Clinical Oncology, 2013, 31, 95-103.	0.8	95
93	Patients with myelodysplastic syndrome and two clones with different interstitial deletions of the long arm of chromosome 5. Leukemia and Lymphoma, 2013, 54, 2314-2317.	0.6	0
94	Comprehensive Analysis of Transcriptome Variation Uncovers Known and Novel Driver Events in T-Cell Acute Lymphoblastic Leukemia. PLoS Genetics, 2013, 9, e1003997.	1.5	110
95	BMI1, The polycombâ€group gene, is recurrently targeted by genomic rearrangements in progressive Bâ€cell leukemia/lymphoma. Genes Chromosomes and Cancer, 2013, 52, 928-944.	1.5	20
96	Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts. Leukemia, 2013, 27, 1760-1763.	3.3	10
97	Cooperativity Of RUNX1 and CSF3R Mutations In The Development Of Leukemia In Severe Congenital Neutropenia: A Unique Pathway In Myeloid Leukemogenesis. Blood, 2013, 122, 444-444.	0.6	1
98	The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories. Blood, 2013, 122, 743-743.	0.6	6
99	JAK2 V617F-Negative and MPL W515K/L-Negative Essential Thrombocythemia: A High Resolution SNP Array Study. Blood, 2013, 122, 5258-5258.	0.6	0
100	Screening JAK2 V617F-Negative and MPL W515K/L-Negative Essential Thrombocythemia Patients For Mutations In SESN2, DNAJC17, ST13, TOP1MT, and NTRK1. Blood, 2013, 122, 5264-5264.	0.6	0
101	Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing. Blood, 2013, 122, 740-740.	0.6	0
102	Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia. Blood, 2013, 122, 1469-1469.	0.6	0
103	Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia, 2012, 26, 1693-1695.	3.3	63
104	t(X;14)(p11.4;q32.33) is recurrent in marginal zone lymphoma and up-regulates GPR34. Haematologica, 2012, 97, 184-188.	1.7	39
105	The different faces of Janus kinase inhibition. Haematologica, 2012, 97, 475-475.	1.7	0
106	Rearrangement of NOTCH1 or BCL3 can independently trigger progression of CLL. Blood, 2012, 119, 3864-3866.	0.6	12
107	Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2â€“positive chronic eosinophilic leukemia. Blood, 2012, 120, 1529-1531.	0.6	63
108	Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. Journal of Allergy and Clinical Immunology, 2012, 130, 607-612.e9.	1.5	604

#	Article	IF	Citations
109	ICON: Eosinophil Disorders. World Allergy Organization Journal, 2012, 5, 174-181.	1.6	25
110	Recurrent breakpoints in 14q32.13/TCL1Aregion in mature B-cell neoplasms with villous lymphocytes. Leukemia and Lymphoma, 2012, 53, 2449-2455.	0.6	3
111	Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Review of Hematology, 2012, 5, 157-176.	1.0	140
112	Targeted Therapy with Rituximab in Felty's Syndrome: A Case Report. Open Rheumatology Journal, 2012, 6, 312-314.	0.1	6
113	Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood, 2012, 119, 4476-4479.	0.6	96
114	Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course. Annals of Hematology, 2012, 91, 863-873.	0.8	65
115	PDS5A, a novel translocation partner of MLL in acute myeloid leukemia. Leukemia Research, 2012, 36, e87-e89.	0.4	5
116	Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?. Leukemia Research, 2012, 36, 832-840.	0.4	21
117	High Accuracy Mutation Detection in Leukemia on a Selected Panel of Cancer Genes. PLoS ONE, 2012, 7, e38463.	1.1	58
118	Translocation t(1;6)(p35.3;p25.2) Involves RCC1 and IRF4 and Is Not Restricted to Unmutated Chronic Lymphocytic Leukemia. Blood, 2012, 120, 4584-4584.	0.6	0
119	Non-IG Aberrations of FOXP1 in B-Cell Malignancies Result in an Aberrant Expression of N-Truncated FOXP1 Isoforms.. Blood, 2012, 120, 2411-2411.	0.6	0
120	Effects of Ponatinib and Other Novel TKI On Growth, Survival, and Function of Neoplastic Eosinophils Carrying FIP1L1/Pdgfra. Blood, 2012, 120, 1760-1760.	0.6	0
121	A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nature Genetics, 2011, 43, 673-678.	9.4	244
122	FOXP1 and PAX5 are rare but recurrent translocations partners in acute lymphoblastic leukemia. Cancer Genetics, 2011, 204, 462-464.	0.2	9
123	Amplification of the G allele at SNP rs6983267 in 8q24 amplicons in myeloid malignancies as cause of the lack of MYC overexpression?. Blood Cells, Molecules, and Diseases, 2011, 47, 259-261.	0.6	5
124	JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood, 2011, 117, 4056-4064.	0.6	103
125	Smad4 binds Hoxa9 in the cytoplasm and protects primitive hematopoietic cells against nuclear activation by Hoxa9 and leukemia transformation. Blood, 2011, 117, 5918-5930.	0.6	29
126	EVI1â€mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells. British Journal of Haematology, 2011, 154, 337-348.	1.2	20

#	Article	IF	Citations
127	PHF6 mutations in adult acute myeloid leukemia. Leukemia, 2011, 25, 130-134.	3.3	142
128	Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia. Cancer Cell, 2011, 19, 740-753.	7.7	124
129	PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. Blood, 2011, 117, 7090-7098.	0.6	76
130	CML with e6a2 BCR-ABL1 transcript: an aggressive entity?. Annals of Hematology, 2011, 90, 1241-1243.	0.8	10
131	The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia, 2011, 25, 1840-1848.	3.3	96
132	External Quality Assessment for KRAS Testing Is Needed: Setup of a European Program and Report of the First Joined Regional Quality Assessment Rounds. Oncologist, 2011, 16, 467-478.	1.9	83
133	The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). Haematologica, 2011, 96, 922-926.	1.7	59
134	Severe congenital neutropenia, a genetically heterogeneous disease group with an increased risk of AML/MDS. Mental Illness, 2011, 3, e9.	0.8	25
135	UPDATE On the RISK of SECONDARY LEUKEMIA In GENETIC SUBGROUPS (ELANE, HAX1, WAS, G6PC3, p14) of CONGENITAL NEUTROPENIA In EUROPE. Blood, 2011, 118, 1106-1106.	0.6	3
136	International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia. Blood, 2011, 118, 2535-2535.	0.6	4
137	Ponatinib Is Active Against the CUX1-FGFR1 Fusion Kinase and Against Imatinib Resistance Mutations of the FIP1L1-PDGFRÎ± Fusion Kinase and of KIT,. Blood, 2011, 118, 3848-3848.	0.6	0
138	T(X;14)(p11.4;q32.33) Is Recurrent In Marginal Zone Lymphoma and Upregulates GPR34. Blood, 2011, 118, 1349-1349.	0.6	0
139	JAK2, As Well As PDL1 and PDL2, are Recurrently Targeted by 9p24 Structural and Numerical Aberrations in Lymphoid Neoplasms of Both B- and T-Cell Origin. Blood, 2011, 118, 2460-2460.	0.6	0
140	ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica, 2010, 95, 509-513.	1.7	89
141	Interphase fluorescence in situ hybridization on selected plasma cells is superior in the detection of cytogenetic aberrations in plasma cell dyscrasia. Genes Chromosomes and Cancer, 2010, 49, 991-997.	1.5	11
142	The t(14;20)(q32;q12): a rare cytogenetic change in multiple myeloma associated with poor outcome. British Journal of Haematology, 2010, 149, 901-904.	1.2	9
143	Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nature Genetics, 2010, 42, 530-535.	9.4	162
144	Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nature Genetics, 2010, 42, 665-667.	9.4	708

#	Article	IF	Citations
145	Coactivated Platelet-Derived Growth Factor Receptor Î± and Epidermal Growth Factor Receptor Are Potential Therapeutic Targets in Intimal Sarcoma. Cancer Research, 2010, 70, 7304-7314.	0.4	80
146	Activating WASP mutations associated with X-linked neutropenia result in enhanced actin polymerization, altered cytoskeletal responses, and genomic instability in lymphocytes. Journal of Experimental Medicine, 2010, 207, 1145-1152.	4.2	67
147	Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 3890-3898.	0.8	217
148	The Kinase Inhibitor TKI258 Is Active Against the Novel CUX1-FGFR1 Fusion Detected In a Patient with T-Lymphoblastic Leukemia/Lymphoma and t(7;8)(q22;p11). Blood, 2010, 116, 2715-2715.	0.6	1
149	Results of An International Study of Quantitative BCR/ABL Assays Using Defined RNA Samples. Blood, 2010, 116, 2742-2742.	0.6	7
150	SMAD4 Sequestrates HOXA9 to Protect Hematopoietic Stem Cells Against Leukemia Transformation. Blood, 2010, 116, 3153-3153.	0.6	3
151	Activating WASP mutations associated with X-linked neutropenia result in enhanced actin polymerization, altered cytoskeletal responses, and genomic instability in lymphocytes. Journal of Cell Biology, 2010, 189, i13-i13.	2.3	0
152	The Interlaboratory RObustness of Next-Generation Sequencing (IRON) Study: Deep-Sequencing Investigating TET2, CBL, and KRAS Mutations In 4464 Amplicons by An International Group Involving 8 Laboratories.. Blood, 2010, 116, 1665-1665.	0.6	0
153	Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe. Blood, 2010, 116, 894-894.	0.6	1
154	G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia. Haematologica, 2009, 94, 1449-1452.	1.7	36
155	Methylation analysis of the imprintedDLK1-GTL2domain supports the random parental origin of theIGH-involving del(14q) in B-cell malignancies. Epigenetics, 2009, 4, 469-475.	1.3	5
156	Recipient-derived chronic lymphocytic leukaemia diagnosed shortly after kidney transplantation on protocol biopsy. Nephrology Dialysis Transplantation, 2009, 24, 3886-3890.	0.4	6
157	Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukinâ€2 stimulation: A Belgian multicentric study. Genes Chromosomes and Cancer, 2009, 48, 843-853.	1.5	54
158	Hepatosplenic Î³Î´ T-cell lymphoma after liver transplantation: Report of the first 2 cases and review of the literature. Liver Transplantation, 2009, 15, 686-692.	1.3	23
159	P052 Acquired mutations in TET2 are common in myelodysplastic syndromes. Leukemia Research, 2009, 33, S88-S89.	0.4	3
160	Neonatal acute myeloid leukemia in an infant whose mother was exposed to diethylstilboestrol in utero. Pediatric Blood and Cancer, 2009, 53, 220-222.	0.8	12
161	A large kindred with Xâ€linked neutropenia with an I294T mutation of the Wiskottâ€Aldrich syndrome gene. British Journal of Haematology, 2009, 144, 120-126.	1.2	90
162	Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. Leukemia, 2009, 23, 125-133.	3.3	65

#	Article	IF	Citations
163	FIP1L1-PDGFRÎ± D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRÎ± T674I eosinophilic leukemia with single agent sorafenib. Leukemia, 2009, 23, 845-851.	3.3	123
164	Translocation t(14;18) is not associated with inferior outcome in chronic lymphocytic leukemia. Leukemia, 2009, 23, 1201-1204.	3.3	35
165	Acquired mutations in TET2 are common in myelodysplastic syndromes. Nature Genetics, 2009, 41, 838-842.	9.4	680
166	Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy. Leukemia Research, 2009, 33, 1703-1705.	0.4	4
167	The fusion proteins TEL-PDGFRÂ and FIP1L1-PDGFRÂ escape ubiquitination and degradation. Haematologica, 2009, 94, 1085-1093.	1.7	43
168	New flow cytometry in hematologic malignancies. Haematologica, 2009, 94, 1639-1641.	1.7	3
169	JAK2 Rearrangements, Including the Novel SEC31A-JAK2 Fusion, Are Recurrent in Classical Hodgkin Lymphoma.. Blood, 2009, 114, 140-140.	0.6	7
170	Update On the Risk of Leukemia in Genetic Subgroups of Congenital Neutropenia (CN): Comparison of Patients with Known Gene Mutations (ELA2, HAX1, WASP, G6PC3, p14).. Blood, 2009, 114, 3597-3597.	0.6	1
171	Deletion of the Protein Tyrosine Phosphatase Gene PTPN2 in T-Cell Acute Lymphoblastic Leukemia.. Blood, 2009, 114, 141-141.	0.6	0
172	Placental Growth Factor: a Novel, Stromal-Derived Target in Human CML.. Blood, 2009, 114, 42-42.	0.6	0
173	BMI1, the Polycomb-Group Gene, Is Recurrently Targeted by Genomic Rearrangements in Progressive B-Cell Leukemia/Lymphoma.. Blood, 2009, 114, 1099-1099.	0.6	13
174	Downregulation of MiR-449a Is Essential for the Survival of EVI1 Positive Leukemic Cells through Modulation of NOTCH1 and BCL2.. Blood, 2009, 114, 361-361.	0.6	0
175	The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: A single centre study of 131 patients. Leukemia Research, 2008, 32, 1026-1035.	0.4	29
176	Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood, 2008, 111, 5683-5690.	0.6	116
177	Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumorâ€“Associated PDGFRAD842V Mutation. Clinical Cancer Research, 2008, 14, 5749-5758.	3.2	116
178	Positron emission tomography in mantle cell lymphoma. Leukemia and Lymphoma, 2008, 49, 1693-1701.	0.6	55
179	EVI1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22. Haematologica, 2008, 93, 1903-1907.	1.7	29
180	In vitro validation of Â-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. Haematologica, 2008, 93, 533-542.	1.7	77

#	Article	IF	Citations
181	t(3;11)(q12;p15)/NUP98-LOC348801 fusion transcript in acute myeloid leukemia. Haematologica, 2008, 93, 1398-1401.	1.7	22
182	High-Dose Therapy in AL Amyloidosis: A Prospective Phase II Study by the Dutch-Belgian Cooperative Group (HOVON). Blood, 2008, 112, 163-163.	0.6	2
183	The T(14;20)(q32;q12) : A Rare Cytogenetic Change in Multiple Myeloma Associated with Poor Outcome. Blood, 2008, 112, 2718-2718.	0.6	0
184	A Myelodysplastic Syndrome Associated with a Clonal GATA1 Mutation.. Blood, 2008, 112, 1243-1243.	0.6	0
185	MicroRNA signatures in Genetic Subtypes of T-Cell Acute Lymphoblastic Leukemia.. Blood, 2008, 112, 3360-3360.	0.6	1
186	Improved Detection of Chromosomal Abnormalities in CLL by Conventional Cytogenetics Using CpG Oligonucleotide and Interleukin-2 Stimulation. A Belgian Multicentric Study. Blood, 2008, 112, 3118-3118.	0.6	0
187	Telomeric IGH Losses Detectable by Fluorescence in Situ Hybridization in Chronic Lymphocytic Leukemia Reflect Somatic VH Recombination Events. Journal of Molecular Diagnostics, 2007, 9, 47-54.	1.2	37
188	Hodgkin lymphoma: Response assessment by Revised International Workshop Criteria. Leukemia and Lymphoma, 2007, 48, 1539-1547.	0.6	68
189	Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by Integrated International Workshop Criteria. Leukemia and Lymphoma, 2007, 48, 1522-1530.	0.6	43
190	Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma?. Leukemia and Lymphoma, 2007, 48, 1745-1754.	0.6	46
191	Array CGH analysis in primary gastrointestinal stromal tumors: Cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status. Genes Chromosomes and Cancer, 2007, 46, 261-276.	1.5	106
192	Fusion gene-mediated truncation ofRUNX1 as a potential mechanism underlying disease progression in the 8p11 myeloproliferative syndrome. Genes Chromosomes and Cancer, 2007, 46, 635-643.	1.5	48
193	Immature and mature monocyte-derived dendritic cells in myelodysplastic syndromes of subtypes refractory anemia or refractory anemia with ringed sideroblasts display an altered cytokine profile. Leukemia Research, 2007, 31, 1373-1382.	0.4	33
194	Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nature Genetics, 2007, 39, 593-595.	9.4	252
195	FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells. Leukemia, 2007, 21, 397-402.	3.3	21
196	A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Leukemia, 2007, 21, 668-677.	3.3	62
197	CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease. Leukemia, 2007, 21, 1451-1459.	3.3	50
198	Interstitial del(14)(q) involving IGH: a novel recurrent aberration in B-NHL. Leukemia, 2007, 21, 2079-2083.	3.3	39

#	Article	IF	Citations
199	Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine. Leukemia, 2007, 21, 1715-1722.	3.3	83
200	Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis. Cancer Genetics and Cytogenetics, 2007, 178, 11-16.	1.0	13
201	Multiple Myeloma with IGH-Involving del(14q): Report of 34 Cases.. Blood, 2007, 110, 991-991.	0.6	1
202	Identification of Novel Genetic Lesions in Myelodysplastic Syndromes Using High Density SNP-Arrays.. Blood, 2007, 110, 2430-2430.	0.6	0
203	Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood, 2006, 107, 3053-3057.	0.6	390
204	Sorafenib is a potent inhibitor of FIP1L1-PDGFRÎ± and the imatinib-resistant FIP1L1-PDGFRÎ± T674I mutant. Blood, 2006, 108, 1374-1376.	0.6	128
205	Coexistence of light chain disease and chronic lymphocytic leukaemia, a complex karyotype with a rapid fatal outcome. International Journal of Laboratory Hematology, 2006, 28, 138-140.	0.2	0
206	CTLA-4 interacts with STAT5 and inhibits STAT5-mediated transcription. Immunology, 2006, 117, 396-401.	2.0	12
207	Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia, 2006, 20, 1496-1510.	3.3	250
208	Transition from EML1-ABL1 to NUP214-ABL1 positivity in a patient with acute T-lymphoblastic leukemia. Leukemia, 2006, 20, 2202-2204.	3.3	10
209	Gain-of-Function WASP Mutations in Pediatric and Adult Patients with Myelodysplasia or AML.. Blood, 2006, 108, 4516-4516.	0.6	1
210	Genetics of t(11;14)(q13;q32)-Negative MCL.. Blood, 2006, 108, 2071-2071.	0.6	0
211	The CD40-Receptor Is Upregulated on Monocytes from Patients with Low-Risk Myelodysplastic Syndromes and Its Inhibition by a Monoclonal Anti-CD40 Antibody Can Increase Colony Formation.. Blood, 2006, 108, 2640-2640.	0.6	0
212	Involvement of the NOTCH1 and NOTCH2 Genes in B-Cell Lymphomagenesis.. Blood, 2006, 108, 2072-2072.	0.6	8
213	X-Linked Neutropenia with a I294T Mutation of the Wiskott-Aldrich Syndrome Gene.. Blood, 2006, 108, 1278-1278.	0.6	0
214	PAD Is a Highly Effective Regimen for the Treatment of Patients with Relapsed Refractory Multiple Myeloma.. Blood, 2006, 108, 5095-5095.	0.6	0
215	Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood, 2005, 105, 4849-4852.	0.6	119
216	Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas. Histopathology, 2005, 46, 431-441.	1.6	50

#	Article	IF	Citations
217	CD34+ marrow progenitors from MDS patients with high levels of intramedullary apoptosis have reduced expression of Î±4Î²1 and Î±5Î²1 integrins. Leukemia, 2005, 19, 57-63.	3.3	28
218	A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias. Leukemia, 2005, 19, 358-366.	3.3	106
219	Identification of e19a2 BCRâ€“ABL fusions (Î¼-BCR breakpoints) at the DNA level by ligation-mediated PCR. Leukemia, 2005, 19, 1292-1295.	3.3	11
220	FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia, 2005, 19, 1299-1305.	3.3	141
221	Quantification of CBFB-MYH11 fusion gene levels in paired peripheral blood and bone marrow samples by real-time PCR. Leukemia, 2005, 19, 1988-1990.	3.3	13
222	Deletion of the inositide-specific phospholipase c Î²1 gene is a rare event in myelodysplastic syndrome and thus of limited value to predict leukemic progression. Leukemia, 2005, 19, 2011-2013.	3.3	5
223	Leukemic recombinations involving heterochromatin in myeloproliferative disorders with t(1;9). Cancer Genetics and Cytogenetics, 2005, 162, 45-49.	1.0	9
224	Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 2005, 7, 387-397.	7.7	2,695
225	NOTCH1 Is Targeted by Ig Translocations in NHL.. Blood, 2005, 106, 4339-4339.	0.6	7
226	Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nature Genetics, 2004, 36, 1084-1089.	9.4	393
227	Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia, 2004, 18, 734-742.	3.3	188
228	Circulating myeloid and lymphoid precursor dendritic cells are clonally involved in myelodysplastic syndromes. Leukemia, 2004, 18, 1451-1456.	3.3	57
229	A flow cytometric method for determination of absolute counts of myeloid precursor dendritic cells in peripheral blood. Journal of Immunological Methods, 2004, 285, 215-221.	0.6	17
230	A male with angioimmunoblastic T-cell lymphoma and proliferative glomerulonephritis. Annals of Hematology, 2004, 83, 455-459.	0.8	14
231	Case of megaloblastic anemia caused by intestinal taeniasis. Annals of Hematology, 2004, 83, 487-488.	0.8	27
232	FOXP1, a Highly Expressed Gene in a Subset of DLBCL, Is Targeted by a Recurrent t(3;14)(p13;q32).. Blood, 2004, 104, 2891-2891.	0.6	1
233	Fusion of NUP214 to ABL1 on Amplified Extrachromosomal Elements in T-ALL.. Blood, 2004, 104, 141-141.	0.6	3
234	Chromosomal Rearrangements Affecting ABL1 in T-Cell Acute Lymphoblastic Leukemia.. Blood, 2004, 104, 2894-2894.	0.6	1

#	Article	IF	Citations
235	Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation. Leukemia, 2003, 17, 458-460.	3.3	6
236	A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome. New England Journal of Medicine, 2003, 348, 1201-1214.	13.9	1,655
237	Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood, 2003, 102, 53-59.	0.6	217
238	ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood, 2003, 102, 2638-2641.	0.6	174
239	Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkinâ€™s lymphoma. Annals of Oncology, 2002, 13, 1356-1363.	0.6	376
240	Comparative Genomic Hybridization Pattern Distinguishes T-Cell/Histiocyte-Rich B-Cell Lymphoma from Nodular Lymphocyte Predominance Hodgkin's Lymphoma. American Journal of Pathology, 2002, 161, 1861-1867.	1.9	67
241	Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation. Journal of Heart and Lung Transplantation, 2002, 21, 1304-1309.	0.3	21
242	Blockade of CTLA-4 enhances allergic sensitization and eosinophilic airway inflammation in genetically predisposed mice. European Journal of Immunology, 2002, 32, 585-594.	1.6	81
243	Aplastic anemia after transplantation for non-A, non-B, non-C fulminant hepatic failure: case report and review of the literature. Transplant International, 2002, 15, 117-123.	0.8	13
244	Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances. Blood, 2001, 97, 1845-1853.	0.6	75
245	Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([¹⁸F]FDG) After First-Line Chemotherapy in Non-Hodgkinâ€™s Lymphoma: Is [¹⁸F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods?. Journal of Clinical Oncology, 2001, 19, 414-419.	0.8	455
246	Autoimmune haemolytic anaemia triggered by Bartonella henselae infection: a case report. British Journal of Haematology, 2001, 115, 924-925.	1.2	27
247	Can positron emission tomography with [18 F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?. British Journal of Haematology, 2001, 115, 272-278.	1.2	159
248	NF-Î° B is involved in the regulation of CD154 (CD40 ligand) expression in primary human T cells. Clinical and Experimental Immunology, 2001, 125, 229-236.	1.1	36
249	Catheter-related bacteremia due to Ewingella americana. Clinical Microbiology and Infection, 2001, 7, 103-104.	2.8	17
250	Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nature Genetics, 2001, 27, 313-317.	9.4	401
251	Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation. Immunology, 1999, 98, 413-421.	2.0	77
252	CD57+/CD28â^' T cells in untreated hemato-oncological patients are expanded and display a Th1-type cytokine secretion profile, ex vivo cytolytic activity and enhanced tendency to apoptosis. Leukemia, 1998, 12, 1573-1582.	3.3	57

#	Article	IF	Citations
253	Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: Evidence for systemic activation of the T cell compartment. Leukemia Research, 1998, 22, 175-184.	0.4	64
254	Lymphocyte profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: flow-cytometric characterization and analysis in a two-dimensional correlation biplot. Annals of Hematology, 1998, 76, 249-256.	0.8	11
255	Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission. British Journal of Haematology, 1998, 102, 486-494.	1.2	38
256	Human CTLA-4 is expressed in situ on T lymphocytes in germinal centers, in cutaneous graft-versus-host disease, and in Hodgkin's disease. American Journal of Pathology, 1998, 152, 963-73.	1.9	18
257	A single course of remission reinduction chemotherapy for acute myelogenous leukemia relapsing after allogeneic bone marrow transplantation is complicated by graft-versus-host disease and followed by sustained complete remission. Leukemia, 1997, 11, 1775-1778.	3.3	6
258	Multivariate reconstruction of lymphocyte profiles in a two-dimensional graphical model as a tool for the investigation of lymphocyte subset distribution in health and disease. , 1997, 28, 220-227.		6
259	Successful control of refractory and life-threatening autoimmune hemolytic anemia with intravenous immunoglobulins in a man with the primary antiphospholipid syndrome. Annals of Hematology, 1996, 73, 253-256.	0.8	10
260	Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poorâ€risk myelodysplastic syndromes. British Journal of Haematology, 1996, 92, 351-359.	1.2	53
261	CD80, CD86 and CD40 Provide Accessory Signals in a Multiple-Step T-Cell Activation Model. Immunological Reviews, 1996, 153, 47-83.	2.8	219
262	Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after singleâ€dose cyclophosphamide combined with rhGMâ€CSF or rhGâ€CSF. British Journal of Haematology, 1995, 90, 384-392.	1.2	31
263	An update on peripheral blood progenitor cell transplantation. Annals of Hematology, 1995, 71, 29-33.	0.8	11
264	Graft-versus-leukemia and graft-versus-lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfusions. Annals of Hematology, 1995, 71, 209-217.	0.8	8
265	Therapy-related acute myeloid leukemia with t(8;16)(p11;p13) following anthracycline-based therapy for nonmetastatic osteosarcoma. Cancer Genetics and Cytogenetics, 1995, 82, 103-105.	1.0	5
266	Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood, 1995, 86, 3660-3667.	0.6	71
267	CD80 (B7-1) and CD86 (B7-2): Potential targets for immunotherapy?. Research in Immunology, 1995, 146, 183-196.	0.9	16
268	The CD28 and CTLA-4 Receptor Family (Part 1 of 2). Chemical Immunology and Allergy, 1994, 59, 62-76.	1.7	12
269	Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells. European Journal of Immunology, 1993, 23, 3120-3125.	1.6	147
270	In situ expression of B7/BB1 on antigenpresenting cells and activated B cells: an immunohistochemical study. International Immunology, 1993, 5, 317-321.	1.8	63

#	Article	IF	Citations
271	The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines. Blood, 1993, 82, 2845-2852.	0.6	73
272	The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines. Blood, 1993, 82, 2845-2852.	0.6	0
273	Ligation of the CD5 or CD28 molecules on resting human T cells induces expression of the early activation antigen CD69 by a calcium- and tyrosine kinase-dependent mechanism. Immunology, 1993, 78, 210-7.	2.0	31
274	Status report of the Leuven isotope separator on-line (LISOL). Nuclear Instruments & Methods in Physics Research B, 1992, 70, 50-55.	0.6	22
275	Immobilized anti-CD5 together with prolonged activation of protein kinase C induce interleukin 2-dependent T cell growth: evidence for signal transduction through CD5. European Journal of Immunology, 1991, 21, 251-259.	1.6	41
276	Crosslinking of the CD5 antigen on human T cells induces functional IL2 receptors. Cellular Immunology, 1990, 131, 109-119.	1.4	13
277	Flow cytometric measurement of cytoplasmic free calcium in human peripheral blood T lymphocytes with fluo-3, a new fluorescent calcium indicator. Journal of Immunological Methods, 1990, 127, 197-205.	0.6	176
278	Cat-scratch disease with reversible encephalopathy. European Journal of Pediatrics, 1989, 149, 24-25.	1.3	5
279	Characterization of ATP-driven calcium uptake in renal basal-lateral and renal endoplasmic reticulum membrane vesicles. Cell Calcium, 1985, 6, 413-429.	1.1	18
280	Genetics of Chronic Lymphocytic Leukemia: Practical Aspects and Prognostic Significance. , 0, , .		2